RSK2 promotes melanoma cell proliferation and vemurafenib resistance <i>via</i> upregulating cyclin D1.

Front Pharmacol · 2022 · PMC9541206 · PMID 36210843

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

RSK2 expression also showed a decreasing trend with the age of melanoma patients ( Figure 1G ).

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.